[Corneal collagen crosslinking with riboflavin for keratoconus patients]

Menga Mengarelli C, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32015001159
Spanish
Authors' objectives: To assess the available evidence on the efficacy, safety and coverage related aspects regarding the use of corneal collagen crosslinking with riboflavin in patients with keratoconus. Keratoconus is a disorder characterized by a progressive and bilateral increase in the corneal curvature with apical thinning, resulting in irregular corneal astigmatism. Its etiology is unknown. It affects children and young individuals; it stabilized after 30 years old. In the general population, its reported frequency is 1/2,000 individuals. Rigid contact lenses, rings or corneal transplantation may be used for therapy Crosslinking with riboflavin (CXL) is proposed as a treatment alternative for mild to moderate keratoconus, alone or as a supplement to other treatments. Crosslinking involves applying a photosensitive product (such as riboflavin) to the cornea and then activate it using type A ultraviolet rays to increase corneal rigidity by creating collagen bridges and thus stopping keratoconus progression.
Authors' recomendations: Low quality evidence is non-conclusive regarding the benefits corneal collagen crosslinking with riboflavin could provide keratoconus patients. Some studies suggest it could slightly improve visual acuity. Some clinical practice guidelines mention this is a treatment option for young people who do not tolerate lenses. Several health sponsors surveyed do not cover it because they consider it experimental and with no proven efficacy.
Details
Project Status: Completed
Year Published: 2015
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Humans
  • Collagen
  • Cornea
  • Keratoconus
  • Riboflavin
Contact
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.